Medikamentöse Therapie von epileptischen Anfällen und Epilepsien

ZUSAMMENFASSUNG Fast jede aktive Epilepsie bedarf einer medikamentösen Therapie durch Antianfallsmedikamente (Antiiktalia). Ziel ist die Anfallsfreiheit des Patienten bei gleichzeitig guter Tolerabilität. Zur Dauertherapie fokaler Epilepsien steht eine Reihe von Antianfallsmedikamenten zur Verfügung, bei generalisierten Epilepsien ist die Auswahl kleiner. Die Wahl des Antianfallsmedikamentes sollte neben dem Epilepsiesyndrom an den individuellen Wünschen und der Lebenssituation des Patienten, seinen Komorbiditäten und dem Nebenwirkungsprofil ausgerichtet werden. Meist wird man deshalb neuere Antianfallsmedikamente bevorzugen. Durch die Entwicklung neuer Medikamente erhöht sich die Chance einer individuell gut verträglichen und erfolgreichen Therapie. Dem gegenüber stehen höhere Therapiekosten der meisten neueren Antianfallsmedikamente. Die meisten epileptischen Anfälle sind selbstlimitierend. Ein prolongierter epileptischer Anfall muss jedoch schnell und ausreichend hoch dosiert mit Benzodiazepinen behandelt werden, um so einen therapierefraktären Verlauf abwenden zu können und das Outcome des Patienten zu verbessern.

• Publication year

  2019

• Venue

  Nervenheilkunde

• Publication date

  2019-12-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/a-0987-8517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Burden and epidemiology of status epilepticus in infants, children, and adolescents: A population‐based study on German health insurance data

  2019cited by this paper
• Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE)

  2019cited by this paper
• General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data

  2019cited by this paper
• Stiripentol for the treatment of seizures associated with Dravet syndrome

  2019cited by this paper
• A pilot, open‐label study of the effectiveness and tolerability of low‐dose ZX008 (fenfluramine HCl) in Lennox‐Gastaut syndrome

  2018cited by this paper
• Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings

  2018cited by this paper
• Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.

  2018influential reference
• Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

  2018cited by this paper
• Gabapentin add-on treatment for drug-resistant focal epilepsy.

  2018cited by this paper
• SENSE registry for status epilepticus

  2018cited by this paper
• Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy.

  2018influential reference
• Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus

  2018cited by this paper
• Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview.

  2018cited by this paper
• Use of Emergency Medication in Adult Patients with Epilepsy: A Multicentre Cohort Study from Germany

  2018cited by this paper
• Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients.

  2018influential reference
• Therapie des akuten konvulsiven Anfalls und Status epilepticus im Kindesalter

  2018cited by this paper
• Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence

  2018cited by this paper
• Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis

  2017influential reference
• Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

  2017cited by this paper
• Concepts for Prehospital and Initial In-hospital Therapy of Status Epilepticus

  2017cited by this paper
• Therapeutic Advances in Neurological Disorders

  2017cited by this paper
• Cannabinoids in treatment-resistant epilepsy: A review.

  2017cited by this paper
• The Burden of Severely Drug-Refractory Epilepsy: A Comparative Longitudinal Evaluation of Mortality, Morbidity, Resource Use, and Cost Using German Health Insurance Data

  2017cited by this paper
• Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

  2017cited by this paper
• Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany

  2017cited by this paper
• Guideline conform initial monotherapy increases in patients with focal epilepsy: A population-based study on German health insurance data.

  2016cited by this paper
• Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond

  2016cited by this paper
• Revised version of quality guidelines for presurgical epilepsy evaluation and surgical epilepsy therapy issued by the Austrian, German, and Swiss working group on presurgical epilepsy diagnosis and operative epilepsy treatment

  2016cited by this paper
• Perampanel as add‐on treatment in refractory focal epilepsy. The Dianalund experience

  2016cited by this paper
• Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2016cited by this paper
• Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.

  2015cited by this paper
• Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2015cited by this paper
• Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.

  2015cited by this paper
• Stiripentol for the treatment of super‐refractory status epilepticus

  2015cited by this paper
• Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic–clonic seizures

  2015cited by this paper
• A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus

  2015cited by this paper
• Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: A multicenter evaluation.

  2015cited by this paper
• The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

  2015cited by this paper
• A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy

  2015cited by this paper
• : A practical clinical definition of epilepsy

  2014influential reference
• Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.

  2014cited by this paper
• Comparative efficacy and tolerability of anti‐epileptic drugs for refractory focal epilepsy: systematic review and network meta‐analysis reveals the need for long term comparator trials

  2013cited by this paper
• Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

  2013cited by this paper
• Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults

  2012cited by this paper
• Intramuscular versus intravenous therapy for prehospital status epilepticus.

  2012cited by this paper
• Leitlinien für Diagnostik und Therapie in der Neurologie

  2012cited by this paper
• Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial.

  2011cited by this paper
• Combining antiepileptic drugs--rational polytherapy?

  2011cited by this paper
• Drug-resistant epilepsy.

  2011cited by this paper
• Epilepsy: Vigabatrin treatment and visual field loss

  2011cited by this paper
• A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations

  2010cited by this paper
• Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.

  2010influential reference
• Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy.

  2009cited by this paper
• Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

  2009cited by this paper
• Cost of epilepsy: a systematic review.

  2008cited by this paper
• Anticonvulsant therapy for status epilepticus.

  2007cited by this paper
• COMPARISON OF LEVETIRACETAM AND CONTROLLED-RELEASE CARBAMAZEPINE IN NEWLY DIAGNOSED EPILEPSY

  2007influential reference
• The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

  2007cited by this paper
• The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

  2007influential reference
• Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands.

  2006cited by this paper
• Assessment of a dose–response relationship of levetiracetam

  2006cited by this paper
• Felbamate: consensus of current clinical experience.

  2006cited by this paper
• Cochrane Database of Systematic Reviews

  2006cited by this paper
• How Long Do Most Seizures Last? A Systematic Comparison of Seizures Recorded in the Epilepsy Monitoring Unit

  2006influential reference
• The epidemiology of epilepsy in Europe – a systematic review

  2005cited by this paper
• Meta-Analysis and Indirect Comparisons of Levetiracetam With Other Second-Generation Antiepileptic Drugs in Partial Epilepsy

  2005influential reference
• Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

  2005cited by this paper
• Randomized dose‐controlled study of topiramate as first‐line therapy in epilepsy

  2005cited by this paper
• Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.

  2005cited by this paper
• Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy

  2003cited by this paper
• Basic Pharmacology of Valproate

  2002cited by this paper
• Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

  2002cited by this paper
• A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.

  2001cited by this paper
• Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study

  2000cited by this paper
• Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy

  1998influential reference
• A comparison of rectal diazepam gel and placebo for acute repetitive seizures.

  1998cited by this paper
• A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy.

  1997cited by this paper
• Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group.

  1995cited by this paper
• How About the New Antiepileptic Drugs?

  1994cited by this paper
• Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.

  1993cited by this paper
• Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture.

  1986cited by this paper

• No citing papers are available for this paper.